Search

Your search keyword '"Perricone, R."' showing total 644 results
Start Over Author "Perricone, R."
644 results on '"Perricone, R."'

1. An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis

Author

Chimenti MS, D'Antonio A, Conigliaro P, Ferrigno S, Vendola A, Ferraioli M, Triggianese P, Costa L, Caso F, and Perricone R

Subjects
psoriatic arthritis, biological therapies, tnf-inhibitors, jak-inhibitors, phosphodiesterase-4, tofacitinib, tsdmards, Medicine (General), R5-920
Abstract

Maria Sole Chimenti,1,* Arianna D’Antonio,1,* Paola Conigliaro,1 Sara Ferrigno,1 Andrea Vendola,1 Mario Ferraioli,1 Paola Triggianese,1 Luisa Costa,2 Francesco Caso,2 Roberto Perricone1 1Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; 2Rheumatology Unit, Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University Federico II, Naples, Italy*These authors contributed equally to this workCorrespondence: Maria Sole Chimenti Tel +39 06 20900358Email maria.sole.chimenti@uniroma2.itAbstract: Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy typically associated with psoriasis (PsO). The pathogenesis is strictly related to the association among the presence of genetic risk alleles and innate and acquired immune response with dramatic consequences on bone remodeling. Clinically, PsA patients may present heterogenicity of articular and periarticular manifestations that may be associated with the presence of comorbidities making treatment decision challenging in patients management. The identification of patient-targeted therapies is still a critical issue. Actually, several biological and synthetic drugs are promising in terms of efficacy and safety profile. National and international treatment recommendations support clinicians in the decision of the best treatment, although they may have limits basically related to updates and different outcomes included in the clinical studies evaluated. The aim of this narrative review is therefore to give guidance for clinicians for PsA patients treatment. For this purpose, we evaluated evidence on biological therapies efficacy used for PsA treatment. Specifically, we reviewed data on biological therapies, Janus kinases (JAK) inhibitors, and drugs with a new mechanism of action that are part of the treatment pipeline. The concept of “switching” and “swapping” is also described, as well as data concerning special populations such as pregnant women and elderly patients.Keywords: psoriatic arthritis, biological therapies, TNF-inhibitors, JAK-inhibitors, phosphodiesterase-4, tofacitinib, tsDMARDs

Published
2020

2. Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

Author

Gioia, C., primary, Picchianti Diamanti, A., additional, Perricone, R., additional, Chimenti, M.S., additional, Afeltra, A., additional, Navarini, L., additional, Migliore, A., additional, Massafra, U., additional, Bruzzese, V., additional, Scolieri, P., additional, Meschini, C., additional, Paroli, M., additional, Caccavale, R., additional, Scapato, P., additional, Scrivo, R., additional, Conti, F., additional, Laganà, B., additional, and Di Franco, M., additional

Published
2023
Full Text
View/download PDF

3. Vincenzo il bombarolo

Author

Valenti, M., Perricone, R., Pantellaro, M. C., Dalai Emiliani, M., Clemente, P., Broccolini, A., Broccolini, A. et all., Bargna, I, Bargna, I., Valenti, M., Perricone, R., Pantellaro, M. C., Dalai Emiliani, M., Clemente, P., Broccolini, A., Broccolini, A. et all., Bargna, I, and Bargna, I.

Published
2023

4. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: A real-life multicentre study

Author

Guidelli, G, Viapiana, O, Luciano, N, De Santis, M, Boffini, N, Quartuccio, L, Birra, D, Conticini, E, Chimenti, M, Bazzani, C, Bruschi, E, Riva, M, Canziani, L, Bianchi, G, Pozzi, M, Limonta, M, Gorla, R, Perricone, R, Frediani, B, Moscato, P, De Vita, S, Dagna, L, Rossini, M, Selmi, C, Guidelli G. M., Viapiana O., Luciano N., De Santis M., Boffini N., Quartuccio L., Birra D., Conticini E., Chimenti M. S., Bazzani C., Bruschi E., Riva M., Canziani L. M., Bianchi G., Pozzi M. R., Limonta M., Gorla R., Perricone R., Frediani B., Moscato P., De Vita S., Dagna L., Rossini M., Selmi C., Guidelli, G, Viapiana, O, Luciano, N, De Santis, M, Boffini, N, Quartuccio, L, Birra, D, Conticini, E, Chimenti, M, Bazzani, C, Bruschi, E, Riva, M, Canziani, L, Bianchi, G, Pozzi, M, Limonta, M, Gorla, R, Perricone, R, Frediani, B, Moscato, P, De Vita, S, Dagna, L, Rossini, M, Selmi, C, Guidelli G. M., Viapiana O., Luciano N., De Santis M., Boffini N., Quartuccio L., Birra D., Conticini E., Chimenti M. S., Bazzani C., Bruschi E., Riva M., Canziani L. M., Bianchi G., Pozzi M. R., Limonta M., Gorla R., Perricone R., Frediani B., Moscato P., De Vita S., Dagna L., Rossini M., and Selmi C.

Abstract

Objective Baricitinib, an oral Janus kinase (JAK) 1-2 inhibitor, is currently used along biologic DMARDs (bDMARDs) after the failure of methotrexate (MTX) in rheumatoid arthritis (RA). We investigated the efficacy and safety of baricitinib in real life. Methods We prospectively enrolled 446 RA patients treated with baricitinib from 11 Italian centres. Patients were evaluated at baseline and after 3, 6, and 12 months. They were arrayed based on previous treatments as bDMARD-naïve and bDMARD-insufficient responders (IR) after the failure or intolerance to bDMARDs. A sub-analysis differentiated the effects of methotrexate (MTX) and the use of oral glucocorticoids (OGC). Results Our cohort included 150 (34%) bDMARD-naïve and 296 (66%) bDMARD-IR patients, with 217 (49%) using baricitinib as monotherapy. Considering DAS-28-CRP as the primary outcome, at 3 and 6 months, 114/314 (36%) and 149/289 (51.6%) patients achieved remission, while those in low disease activity (LDA) were 62/314 (20%) and 46/289 (15.9%), respectively; finally at 12 months 81/126 (64%) were in remission and 21/126 (17%) in LDA. At all-timepoints up to 12 months, bDMARDs-naïve patients demonstrated a better clinical response, independently of MTX. A significant reduction in the OGC dose was observed at 3 and 12 months in all groups. The serum positivity for both rheumatoid factors (RF) and anti-citrullinated protein antibodies (ACPA) conferred a lower risk of stopping baricitinib due to inefficacy. Fifty-eight (13%) patients discontinued baricitinib due to adverse events, including thrombotic events and herpes zoster reactivation. Conclusion Real-life data confirm the efficacy and safety profiles of baricitinib in patients with RA and provide evidence that drug survival is higher in bDMARDs-naïve and seropositive patients.

Published
2021

5. Baseline characteristics of systemic lupus erythematosus patients included in the Lupus Italian Registry of the Italian Society for Rheumatology

Author

Sebastiani, G, Spinelli, F, Bartoloni, E, Bortoluzzi, A, Bozzolo, E, Canofari, C, Canti, V, Conigliaro, P, Ditto, M, Emmi, G, Franceschini, F, Frassi, M, Iaccarino, L, Iuliano, A, Manfredi, A, Pacucci, V, Parisi, S, Pazzola, G, Perricone, R, Prevete, I, Ramirez, G, Scarpato, S, Scirocco, C, Silvagni, E, Zen, M, Zanetti, A, Carrara, G, Scire, C, Conti, F, Doria, A, Sebastiani G. D., Spinelli F. R., Bartoloni E., Bortoluzzi A., Bozzolo E., Canofari C., Canti V., Conigliaro P., Ditto M. C., Emmi G., Franceschini F., Frassi M., Iaccarino L., Iuliano A., Manfredi A., Pacucci V., Parisi S., Pazzola G., Perricone R., Prevete I., Ramirez G. A., Scarpato S., Scirocco C., Silvagni E., Zen M., Zanetti A., Carrara G., Scire C. A., Conti F., Doria A., Sebastiani, G, Spinelli, F, Bartoloni, E, Bortoluzzi, A, Bozzolo, E, Canofari, C, Canti, V, Conigliaro, P, Ditto, M, Emmi, G, Franceschini, F, Frassi, M, Iaccarino, L, Iuliano, A, Manfredi, A, Pacucci, V, Parisi, S, Pazzola, G, Perricone, R, Prevete, I, Ramirez, G, Scarpato, S, Scirocco, C, Silvagni, E, Zen, M, Zanetti, A, Carrara, G, Scire, C, Conti, F, Doria, A, Sebastiani G. D., Spinelli F. R., Bartoloni E., Bortoluzzi A., Bozzolo E., Canofari C., Canti V., Conigliaro P., Ditto M. C., Emmi G., Franceschini F., Frassi M., Iaccarino L., Iuliano A., Manfredi A., Pacucci V., Parisi S., Pazzola G., Perricone R., Prevete I., Ramirez G. A., Scarpato S., Scirocco C., Silvagni E., Zen M., Zanetti A., Carrara G., Scire C. A., Conti F., and Doria A.

Abstract

Objective: To report baseline data of SLE patients enrolled in the Lupus Italian Registry (LIRE). Methods: Patients affected by SLE aged ≥ 16 years were consecutively recruited in a multicenter prospective study comparing two cohorts: patients starting biologic immunosuppressants (BC) and patients starting non-biologic immunosuppresants (NBC). Results: 308 patients were enrolled, 179 in NBC and 129 in BC. Mean age at disease onset and at diagnosis was significantly higher in NBC (p = 0.023, p = 0.045, respectively). Disease duration was longer in BC (p = 0.022). Patients in BC presented arthritis more frequently (p = 0.024), those in NBC nephropathy (p = 0.03). Quality of life was worse in BC (p = 0.031). Anti-dsDNA, low C3, were significantly more frequent in BC (p < 0.001, p = 0.009, respectively). Mycophenolate, methotrexate and azathioprine were the drugs more frequently prescribed in NBC, Belimumab and Rituximab in BC. Conclusion: The predominant organ involvement was different in the two cohorts: kidney involvement predominated in NBC, joint involvement in BC. Despite the younger age at disease onset, patients of the BC had a longer disease duration and more frequently had taken a cumulative prednisone dosage greater than 10 g. Even the pattern of clinical manifestations inducing to prescribe biological rather than conventional immunosuppressants was quite different. Keywords: Autoantibody(ies), autoimmune disease, belimumab, cohort studies, glucocorticoids, immunosuppressants, rituximab, systemic lupus erythematosus.

Published
2021

6. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study

Author

Giacomo Maria Guidelli, Viapiana, O., Luciano, N., Santis, M., Boffini, N., Quartuccio, L., Birra, D., Conticini, E., Chimenti, M. S., Bazzani, C., Bruschi, E., Riva, M., Canziani, L. M., Bianchi, G., Pozzi, M. R., Limonta, M., Gorla, R., Perricone, R., Frediani, B., Moscato, P., Vita, S., Dagna, L., Rossini, M., and Selmi, C.

Subjects
rheumatoid arthritis, Sulfonamides, Immunology, Settore MED/16, baricitinib, dmards, rheumatoid arthritis, Arthritis, Rheumatoid, Methotrexate, Treatment Outcome, Rheumatology, Purines, Antirheumatic Agents, baricitinib, Azetidines, Humans, Pyrazoles, Immunology and Allergy, Drug Therapy, Combination, dmards
Abstract

Baricitinib, an oral Janus kinase (JAK) 1-2 inhibitor, is currently used along biologic DMARDs (bDMARDs) after the failure of methotrexate (MTX) in rheumatoid arthritis (RA). We investigated the efficacy and safety of baricitinib in real life.We prospectively enrolled 446 RA patients treated with baricitinib from 11 Italian centres. Patients were evaluated at baseline and after 3, 6, and 12 months. They were arrayed based on previous treatments as bDMARD-naïve and bDMARD-insufficient responders (IR) after the failure or intolerance to bDMARDs. A sub-analysis differentiated the effects of methotrexate (MTX) and the use of oral glucocorticoids (OGC).Our cohort included 150 (34%) bDMARD-naïve and 296 (66%) bDMARD-IR patients, with 217 (49%) using baricitinib as monotherapy. Considering DAS-28-CRP as the primary outcome, at 3 and 6 months, 114/314 (36%) and 149/289 (51.6%) patients achieved remission, while those in low disease activity (LDA) were 62/314 (20%) and 46/289 (15.9%), respectively; finally at 12 months 81/126 (64%) were in remission and 21/126 (17%) in LDA. At all-timepoints up to 12 months, bDMARDs-naïve patients demonstrated a better clinical response, independently of MTX. A significant reduction in the OGC dose was observed at 3 and 12 months in all groups. The serum positivity for both rheumatoid factors (RF) and anti-citrullinated protein antibodies (ACPA) conferred a lower risk of stopping baricitinib due to inefficacy. Fifty-eight (13%) patients discontinued baricitinib due to adverse events, including thrombotic events and herpes zoster reactivation.Real-life data confirm the efficacy and safety profiles of baricitinib in patients with RA and provide evidence that drug survival is higher in bDMARDs-naïve and seropositive patients.

Published
2021
Full Text
View/download PDF

7. Profile of certolizumab and its potential in the treatment of psoriatic arthritis

Author

Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, and Perricone R

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Maria Sole Chimenti,1 Rosita Saraceno,2 Andrea Chiricozzi,2,3 Alessandro Giunta,2 Sergio Chimenti,2 Roberto Perricone11Unit of Rheumatology, Allergology, and Clinical Immunology, 2Unit of Dermatology, University of Rome Tor Vergata, Rome, Italy; 3Laboratory for Investigative Dermatology, Rockefeller University, New York, NY, USAAbstract: Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy associated with psoriasis (PsO). PsA could be considered an enthesal disease because of the link between mechanical stress (entheses) and immunologically active tissue (synovium). Evidence of efficacy of anti-tumor necrosis factor alpha (TNF-α) is supported by reduction of histological vascularity and immune cell infiltrates in synovial tissue after treatment. Certolizumab pegol (CZP) is a polyethylene glycolylated (PEGylated) Fab′ fragment of a humanized monoclonal antibody that binds and neutralizes human TNF-α. The PEG moiety of the Fab fragment, markedly increases the half-life of CZP and confers to the drug a unique structure that differs from the other anti-TNF-α agents tested for the treatment of Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis, nonradiographic spondyloarthritis, PsO, and PsA. In contrast to other anti-TNF-α agents, CZP did not mediate increased levels of apoptosis, suggesting that these mechanisms are not essential for the anti-TNF-α efficacy in Crohn’s disease. As CZP, infliximab, and adalimumab, but not etanercept, almost completely inhibited lipopolysaccharide-induced interleukin-1 beta release from monocytes, this cytokine-production inhibition may be relevant for drug efficacy. Due to these characteristics, it has been demonstrated in clinical studies that CZP effectively improves signs and symptoms of arthritis and physical function and skin manifestations of PsO, with a safety profile similar to rheumatoid arthritis. This drug can be considered as a valid treatment in patients affected by PsA. The efficacy and tolerability profiles suggest CZP as a suitable antipsoriatic drug in the treatment of PsA.Keywords: psoriatic arthritis, certolizumab pegol, biological therapies, anti-TNF

Published
2013

8. AB0380 ANTI-TNFα: ORIGINATORS vs BIOSIMILARS, COMPARISON IN CLINICAL RESPONSE ASSESSMENT IN A MULTICENTER COHORT OF PATIENTS WITH INFLAMMATORY ARTHROPATHIES

Author

Gioia, C., primary, Picchianti-Diamanti, A., additional, Perricone, R., additional, Chimenti, M. S., additional, Afeltra, A., additional, Navarini, L., additional, Migliore, A., additional, Massafra, U., additional, Bruzzese, V., additional, Scolieri, P., additional, Meschini, C., additional, Scapato, P., additional, Paroli, M., additional, Scrivo, R., additional, Conti, F., additional, Laganà, B., additional, and Di Franco, M., additional

Published
2022
Full Text
View/download PDF

9. POS0721 ASSOCIATION BETWEEN PRECONCEPTION COMPLEMENT LEVELS AND USE OF HYDROXYCHLOROQUINE WITH PREGNANCY OUTCOME IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME AND CARRIERS OF ANTIPHOSPHOLIPID ANTIBODIES: AN INTERNATIONAL MULTICENTER STUDY

Author

Lini, D., primary, Nalli, C., additional, Andreoli, L., additional, Crisafulli, F., additional, Fredi, M., additional, Lazzaroni, M. G., additional, Bitsadze, V., additional, Calligaro, A., additional, Canti, V., additional, Caporali, R., additional, Carubbi, F., additional, Chighizola, C., additional, Conigliaro, P., additional, Conti, F., additional, De Carolis, C., additional, Del Ross, T., additional, Favaro, M., additional, Gerosa, M., additional, Iuliano, A., additional, Khizroeva, J., additional, Makatsariya, A., additional, Meroni, P. L., additional, Mosca, M., additional, Padovan, M., additional, Perricone, R., additional, Rovere-Querini, P., additional, Sebastiani, G. D., additional, Tani, C., additional, Tonello, M., additional, Truglia, S., additional, Zucchi, D., additional, Franceschini, F., additional, and Tincani, A., additional

Published
2022
Full Text
View/download PDF

10. FORME E FUNZIONI DEI SIMULACRI E DEI FANTOCCI ANIMATI NELLE FESTE SICILIANE

Author

Buttitta, I, Perricone, R, Pasqualino, C, Dufrene, T, Buttitta, I, Perricone, R, Vidal, D, Grimaud, E, Paré, Z, Gonzàlez Alcantud, JA, and Leone, A

Subjects
rituals artifacts, anthropomorphic and theriomorphic puppets, religious festivals, Sicily, Settore M-DEA/01 - Discipline Demoetnoantropologiche, manufatti rituali, pupi antropomorfi e teriomorfi, feste religiose, Sicilia
Abstract

In Sicilia, in occasione di numerose cerimonie religiose, soprattutto a Pasqua, entrano in scena statue con arti mobili (soprattutto Crocifissi e Madonne) e fantocci antropomorfi o teriomorfi animati da un manipolatore posto al loro interno. Se dal punto di vista fenomenologico, questi ultimi artefatti, costituiscono un ibrido, un incrocio tra umano e artificiale, dai punti di vista funzionale e simbolico, sia che rappresentino i santi apostoli sia che rappresentino eroi fondatori o animali leggendari, si pro-pongono, sempre e comunque, come entità altre dall’umano. I fantocci animati, pertanto, al pari dei mascherati e dei simulacri processionali dei santi, sono da considerarsi delle epifanie di una “alterità” con cui bisogna mantenere un sistema di relazioni positive al fine di garantire la ciclica ricostituzione dell’ordine naturale e sociale. Non a caso, quando irrompono nello spazio comunitario, sono caratte-rizzati da un lato da comportamenti a-normali, tesi a enfatizzarne la diversità e la non-umanità, dall’altro sono destinatari di offerte che rinnovano quel circuito del dono che sempre sostanzia ai rap-porti tra immanenza e trascendenza. In tutti casi, inoltre, le loro peculiarità morfologiche e i loro singo-lari comportamenti performativi, non di rado tricksterici e predatori, rivelano un modo “altro” di vivere il sacro e, più in generale, un modo di vivere “altro” che li propone come espressioni totemiche di una specifica appartenenza comunitaria. In Sicily, on the occasion of numerous religious ceremonies, especially at Easter, statues with movable limbs (especially Crucifixes and Madonnas) and anthropomorphic or theriomorphic puppets animated by a manipulator placed inside them enter the scene. If from a phenomenological point of view, these last artifacts constitute a hybrid, a cross between human and artificial, from a functional and symbolic point of view, whether they represent the holy apostles or that they represent founding heroes or legendary animals, they propose, always and in any case, as entities other than the human. The animated puppets, therefore, like the masked ones and the processional simulacra of the saints, are to be considered epiphanies of an "otherness" with which it is necessary to maintain a system of positive relationships in order to guarantee the cyclical reconstitution of the natural and social order. It is no coincidence that when they break into the community space, they are characterized on the one hand by a-normal behaviour, aimed at emphasizing their diversity and non-humanity, and on the other they are recipients of offers which renew that circuit of the gift which always substantiates to the relationship between immanence and transcendence. In all cases, moreover, their morphological peculiarities and their singular performative behaviors, often tricksteric and predatory, reveal an "other" way of experiencing the sacred and, more generally, an "other" way of living than proposes as totemic expressions of a specific community membership.

Published
2021

12. Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies

Author

Andreoli, L, Gerardi, M, Fernandes, M, Bortoluzzi, A, Bellando-Randone, S, Brucato, A, Caporali, R, Chighizola, C, Chimenti, M, Conigliaro, P, Cutolo, M, Cutro, M, D'Angelo, S, Doria, A, Elefante, E, Fredi, M, Galeazzi, M, Gerosa, M, Govoni, M, Iuliano, A, Larosa, M, Lazzaroni, M, Matucci-Cerinic, M, Meroni, M, Meroni, P, Mosca, M, Patane, M, Pazzola, G, Pendolino, M, Perricone, R, Ramoni, V, Salvarani, C, Sebastiani, G, Selmi, C, Spinelli, F, Valesini, G, Scire, C, Tincani, A, Andreoli L., Gerardi M. C., Fernandes M., Bortoluzzi A., Bellando-Randone S., Brucato A., Caporali R., Chighizola C. B., Chimenti M. S., Conigliaro P., Cutolo M., Cutro M. S., D'Angelo S., Doria A., Elefante E., Fredi M., Galeazzi M., Gerosa M., Govoni M., Iuliano A., Larosa M., Lazzaroni M. G., Matucci-Cerinic M., Meroni M., Meroni P. L., Mosca M., Patane M., Pazzola G., Pendolino M., Perricone R., Ramoni V., Salvarani C., Sebastiani G. D., Selmi C., Spinelli F. R., Valesini G., Scire C. A., Tincani A., Andreoli, L, Gerardi, M, Fernandes, M, Bortoluzzi, A, Bellando-Randone, S, Brucato, A, Caporali, R, Chighizola, C, Chimenti, M, Conigliaro, P, Cutolo, M, Cutro, M, D'Angelo, S, Doria, A, Elefante, E, Fredi, M, Galeazzi, M, Gerosa, M, Govoni, M, Iuliano, A, Larosa, M, Lazzaroni, M, Matucci-Cerinic, M, Meroni, M, Meroni, P, Mosca, M, Patane, M, Pazzola, G, Pendolino, M, Perricone, R, Ramoni, V, Salvarani, C, Sebastiani, G, Selmi, C, Spinelli, F, Valesini, G, Scire, C, Tincani, A, Andreoli L., Gerardi M. C., Fernandes M., Bortoluzzi A., Bellando-Randone S., Brucato A., Caporali R., Chighizola C. B., Chimenti M. S., Conigliaro P., Cutolo M., Cutro M. S., D'Angelo S., Doria A., Elefante E., Fredi M., Galeazzi M., Gerosa M., Govoni M., Iuliano A., Larosa M., Lazzaroni M. G., Matucci-Cerinic M., Meroni M., Meroni P. L., Mosca M., Patane M., Pazzola G., Pendolino M., Perricone R., Ramoni V., Salvarani C., Sebastiani G. D., Selmi C., Spinelli F. R., Valesini G., Scire C. A., and Tincani A.

Abstract

Pregnancy requires a special management in women with inflammatory rheumatic diseases (RDs), with the aim of controlling maternal disease activity and avoiding fetal complications. Despite the heterogeneous course of RDs during pregnancy, their impact on pregnancy largely relates to the extent of active inflammation at the time of conception. Therefore, accurate evaluation of disease activity is crucial for the best management of pregnant patients. Nevertheless, there are limitations in using conventional measures of disease activity in pregnancy, as some items included in these instruments can be biased by symptoms or by physiological changes related to pregnancy and the pregnancy itself may influence laboratory parameters used to assess disease activity. This article aims to summarize the current literature about the available instruments to measure disease activity during pregnancy in RDs. Systemic lupus erythematosus is the only disease with instruments that have been modified to account for several adaptations which might interfere with the attribution of signs or symptoms to disease activity during pregnancy. No modified-pregnancy indices exist for women affected by other RDs, but standard indices have been applied to pregnant patients. The current body of knowledge shows that the physiologic changes that occur during pregnancy need to be either adapted from existing instruments or developed to improve the management of pregnant women with RDs. Standardized instruments to assess disease activity during pregnancy would be helpful not only for clinical practice but also for research purposes.

Published
2019

13. Post-fotografia etnografica

Author

Perricone R. and Perricone R.

Subjects
photo, rite, animism, selfie, animismo, fotografie, rito
Abstract

Sommario: È evidente come la nostra società tecnologica sia legata senza alcun dubbio alla diffusione delle immagini. Autori come Gottfried Boehm, John Mitchell, Hans Belting hanno indagato la natura dell'immagine ponendo le basi, negli anni Novanta, per l'idea di un pictorial turn, di una cultura totalmente dominata dalle immagini che è diventata adesso una possibilità tecnica reale su scala globale. Un nuovo statuto dell'immagine che si usa raccogliere sotto l'etichetta di iconic turner inserito nel più vasto campo visual culture studies. Summary: It is evident that our technological society is undoubtedly linked to the diffusion of images. Authors such as Gottfried Boehm, John Mitchell, Hans Belting investigated the nature of the image by laying the foundations, in the 1990s, for the idea of ​​a pictorial turn, of a culture totally dominated by images that has now become a real technical possibility on global scale. A new statute of the image that is used to collect under the label of iconic turner inserted in the wider field of visual culture studies.

Published
2020

17. The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

Author

Giacomelli, R. Afeltra, A. Bartoloni, E. Berardicurti, O. Bombardieri, M. Bortoluzzi, A. Carubbi, F. Caso, F. Cervera, R. Ciccia, F. Cipriani, P. Coloma-Bazán, E. Conti, F. Costa, L. D'Angelo, S. Distler, O. Feist, E. Foulquier, N. Gabini, M. Gerber, V. Gerli, R. Grembiale, R.D. Guggino, G. Hoxha, A. Iagnocco, A. Jordan, S. Kahaleh, B. Lauper, K. Liakouli, V. Lubrano, E. Margiotta, D. Naty, S. Navarini, L. Perosa, F. Perricone, C. Perricone, R. Prete, M. Pers, J.-O. Pitzalis, C. Priori, R. Rivellese, F. Ruffatti, A. Ruscitti, P. Scarpa, R. Shoenfeld, Y. Triolo, G. Tzioufas, A.

Abstract

Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in choosing the right treatment, the best timing of administration, consequently trying to maximize drug efficacy, and, possibly, reducing adverse events. In this work, the growing body of evidence is summarized regarding the predictive factors for drug response in patients with AIDs, applying the precision medicine principles to provide high-quality evidence for therapeutic opportunities in improving the management of these patients. © 2020

Published
2021

18. THE PSABio STUDY IN ITALY: A REAL-WORLD COMPARISON OF THE PERSISTENCE, EFFECTIVENESS AND SAFETY OF USTEKINUMAB AND TUMOUR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS

Author

Gremese, E., Ciccia, F., Selmi, C., Cuomo, G., Foti, R., Cerinic, M. Matucci, Conti, F., Fusaro, E., Guggino, G., Iannone, F., Delle Sedie, A., Perricone, R., Idolazzi, L., Moscato, P., Theander, E., Noel, W., Bergmans, P., Marelli, S., Gossec, L., and Smolen, J. S.

Subjects
Psortiatic arthritis biologic agent ustekinumab
Published
2021

20. Il collezionismo come pratica culturale

Author

Schneider, A, Faeta, F, Severi, F, Cometa, M, Fabbri, P, Simonicca, A, Migliore, T, Buttitta, IE, Pasqualino, C, D'Agostino, G, Marrone, G, Di Stefano, E, Faletra, M, Mangano, D, Perricone, R, Marano, F, Padiglione, V, Santanera, G, Bargna, L, Bargna, LI, Schneider, A, Faeta, F, Severi, F, Cometa, M, Fabbri, P, Simonicca, A, Migliore, T, Buttitta, IE, Pasqualino, C, D'Agostino, G, Marrone, G, Di Stefano, E, Faletra, M, Mangano, D, Perricone, R, Marano, F, Padiglione, V, Santanera, G, Bargna, L, and Bargna, LI

Abstract

Cosa sia una collezione è noto a tutti e tuttavia, se ci interroghiamo su che cosa tenga insieme attività e oggetti molto diversi fra loro sotto il segno della collezione, le cose non sono più tanto chiare: si tratta di pratiche culturali diverse che presentano somiglianze ma anche profonde discontinuità. Collezionare è molto di più che raccogliere e accumu- lare degli oggetti, è una pratica di costruzione del sapere attraverso la quale si dà forma alla realtà, la si rappresenta e la si espone in forma pubblica o privata: è un modo di darsi ragione del mondo, di costruire un microcosmo tra reale e immaginario che ci parla tanto degli altri come di noi. E un pensiero concreto che si fa con le cose. È lo spazio in cui si mette ordine nel mondo o nella propria vita, ma anche un modo per esplorare altre possibilità. È uno dei luoghi in cui gruppi e persone articolano la propria biografia e costruiscono la propria identità e quella degli altri. Partendo dalle ricerche etnografiche svolte in Italia e in Camerun, Ivan Bargna riflette sulle forme contemporanee del “collezionare” nella quotidianità e nell’arte, dai musei alla discarica, dall’accumulazione compulsiva di cose ed esperienze all’arte di disfarsene, dalle cabine armadio delle nostre case ai tesori dei re dei Grassfields camerunesi. Il collezionismo appare così non la mania di persone eccentriche (o una prerogativa esclusiva dell’occidente) ma come indicatore di dinamiche sociali e culturali più ampie, localmente diversificate e attraversate da flussi globali.

Published
2021

24. POS1021 THE PsABio STUDY IN ITALY: A REAL-WORLD COMPARISON OF THE PERSISTENCE, EFFECTIVENESS AND SAFETY OF USTEKINUMAB AND TUMOUR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS

Author

Gremese, E., primary, Ciccia, F., additional, Selmi, C., additional, Cuomo, G., additional, Foti, R., additional, Matucci Cerinic, M., additional, Conti, F., additional, Fusaro, E., additional, Guggino, G., additional, Iannone, F., additional, Delle Sedie, A., additional, Perricone, R., additional, Idolazzi, L., additional, Moscato, P., additional, Theander, E., additional, Noel, W., additional, Bergmans, P., additional, Marelli, S., additional, Gossec, L., additional, and Smolen, J. S., additional

Published
2021
Full Text
View/download PDF

26. POS0737 LOW PRECONCEPTIONAL COMPLEMENT LEVEL IS RELATED WITH ADVERSE OBSTETRIC OUTCOME IN A MULTICENTRIC COHORT OF PREGNANCY IN PATIENTS WITH APS AND APL POSITIVITY

Author

Lini, D., primary, Nalli, C., additional, Andreoli, L., additional, Crisafulli, F., additional, Fredi, M., additional, Lazzaroni, M. G., additional, Bitsadze, V., additional, Calligaro, A., additional, Canti, V., additional, Caporali, R., additional, Carubbi, F., additional, Chighizola, C., additional, Conigliaro, P., additional, Conti, F., additional, De Carolis, C., additional, Del Ross, T., additional, Favaro, M., additional, Gerosa, M., additional, Iuliano, A., additional, Khizroeva, J., additional, Makatsariya, A., additional, Meroni, P. L., additional, Mosca, M., additional, Melissa, P., additional, Perricone, R., additional, Rovere-Querini, P., additional, Sebastiani, G. D., additional, Tani, C., additional, Tonello, M., additional, Truglia, S., additional, Zucchi, D., additional, Franceschini, F., additional, and Tincani, A., additional

Published
2021
Full Text
View/download PDF

28. AB0467 EFFECTIVENESS OF GOLIMUMAB AFTER TNF-INHIBITOR FAILURE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, OR AXIAL SPONDYLOARTHRITIS: RESULTS AT 3 MONTHS FROM THE GO-BEYOND ITALY STUDY

Author

D’angelo, S., primary, Tirri, E., additional, Giardino, A. M., additional, Matucci-Cerinic, M., additional, Dagna, L., additional, Santo, L., additional, Ciccia, F., additional, Frediani, B., additional, Govoni, M., additional, Bobbio Pallavicini, F., additional, Grembiale, R. D., additional, Delle Sedie, A., additional, Cercone, S., additional, Mule’, R., additional, Cantatore, F. P., additional, Foti, R., additional, Gremese, E., additional, Perricone, R., additional, Salaffi, F., additional, Viapiana, O., additional, Cauli, A., additional, Giacomelli, R., additional, Arcarese, L., additional, Guggino, G., additional, Russo, R., additional, Capocotta, D., additional, Nacci, F., additional, Anelli, M. G., additional, Picerno, V., additional, and Iannone, F., additional

Published
2021
Full Text
View/download PDF

32. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart

Author

Perricone C, Conigliaro P, Ciccacci C, Marcucci E, Giacomo Cafaro, Bartoloni E, Perricone R, Novelli G, Borgiani P, and Gerli R

Subjects
Antigens, Differentiation, T-Lymphocyte, Pneumonia, Viral, Antibodies, Monoclonal, Humanized, Polymorphism, Single Nucleotide, Antibodies, Arthritis, Rheumatoid, Betacoronavirus, Antigens, CD, Rheumatoid, Lectins, Monoclonal, Receptors, 80 and over, Humans, Lectins, C-Type, Viral, Antigens, Polymorphism, Pandemics, Humanized, Adaptor Proteins, Signal Transducing, Aged, Aged, 80 and over, C-Type, SARS-CoV-2, Interleukin-6, Arthritis, Signal Transducing, COVID-19, Adaptor Proteins, Pneumonia, Single Nucleotide, Middle Aged, Receptors, Interleukin-6, CD, T-Lymphocyte, Settore MED/03, Differentiation, Coronavirus Infections
Published
2020

36. PBI57 Effectiveness of Biologic Treatments for Psoriatic Arthritis in Italy: Preliminary Results of the Chronos Study

Author

Colombo, D., primary, Simoni, L., additional, Ori, A., additional, Fiocchi, M., additional, Frassi, M., additional, Pagano Mariano, G., additional, Fusaro, E., additional, Lomater, C., additional, Del Medico, P., additional, Iannone, F., additional, Foti, R., additional, Limonta, M., additional, Marchesoni, A., additional, Raffeiner, B., additional, Viapiana, O., additional, Grassi, W., additional, Grembiale, R.D., additional, Guggino, G., additional, Faggioli, P., additional, Tirri, E., additional, Perricone, R., additional, Sarzi Puttini, P.C., additional, De Vita, S., additional, Conti, F., additional, and Zagni, E., additional

Published
2020
Full Text
View/download PDF

37. SAT0153 GENDER DOES NOT INFLUENCE CLINICAL RESPONSE TO JAK INHIBITORS IN RHEUMATOID ARTHRITIS: AN ITALIAN MULTICENTRE ANALYSIS

Author

Spinelli, F. R., primary, Chimenti, M. S., additional, Vadacca, M., additional, Iannuccelli, C., additional, Conigliaro, P., additional, Bosello, S. L., additional, Ceccarelli, F., additional, Garufi, C., additional, Raffone, G., additional, Di Noi, P., additional, Bruno, D., additional, Afeltra, A., additional, Perricone, R., additional, Conti, F., additional, and Gremese, E., additional

Published
2020
Full Text
View/download PDF

38. AB0640 LONG-TERM EFFECTIVENESS AND DRUG SURVIVAL OF GOLIMUMAB IN PATIENTS AFFECTED BY PSORIATIC ARTHRITIS WITH CUTANEOUS INVOLVEMENT

Author

Fonti, G. L., primary, Chimenti, M. S., additional, D’antonio, A., additional, Teoli, M., additional, Caso, F., additional, Costa, L., additional, Tasso, M., additional, Ortolan, A., additional, Lorenzin, M., additional, Conigliaro, P., additional, Triggianese, P., additional, Scarpa, R., additional, Perricone, R., additional, and Ramonda, R., additional

Published
2020
Full Text
View/download PDF

39. FRI0270 ONE-YEAR EFFECTIVENESS, RETENTION RATE AND SAFETY OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: A REAL-LIFE MULTICENTRE STUDY

Author

Chimenti, M. S., primary, Fonti, G. L., additional, Conigliaro, P., additional, Sunzini, F., additional, Scrivo, R., additional, Navarini, L., additional, Triggianese, P., additional, Peluso, G., additional, Scolieri, P., additional, Caccavale, R., additional, Picchianti-Diamanti, A., additional, De Martino, E., additional, Salemi, S., additional, Birra, D., additional, Altobelli, A., additional, Paroli, M., additional, Bruzzese, V., additional, Laganà, B., additional, Gremese, E., additional, Conti, F., additional, Afeltra, A., additional, and Perricone, R., additional

Published
2020
Full Text
View/download PDF

50. TNFAIP3 Gene Polymorphisms in Three Common Autoimmune Diseases: Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Primary Sjogren Syndrome—Association with Disease Susceptibility and Clinical Phenotypes in Italian Patients

Author

Ciccacci, C., primary, Latini, A., additional, Perricone, C., additional, Conigliaro, P., additional, Colafrancesco, S., additional, Ceccarelli, F., additional, Priori, R., additional, Conti, F., additional, Perricone, R., additional, Novelli, G., additional, and Borgiani, P., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results